Age-Related Macular Degeneration in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031

• 1 Age-Related Macular Degeneration: Executive Summary

  • 1.1 AMD market will grow significantly during the forecast period, reaching sales of $27.5 billion in 2031
  • 1.2 Development of cell-based and gene therapies represents a new paradigm for AMD
  • 1.3 Reducing treatment burden is an important unmet need for wet AMD
  • 1.4 Treatment for geographic atrophy and dry AMD represents an important unmet need for AMD
  • 1.5 Late-stage pipeline therapies are anticipated to drive growth in the AMD market
  • 1.6 What do physicians think?

• 2 Introduction

  • 2.1 Catalyst
  • 2.2 Related reports
  • 2.3 Upcoming reports

• 3 Disease Overview

  • 3.1 Etiology and pathophysiology

    • 3.1.1 Overview
    • 3.1.2 Etiology
    • 3.1.3 Pathophysiology

  • 3.2 Classification or staging systems

• 4 Epidemiology

  • 4.1 Disease background
  • 4.2 Risk factors and comorbidities
  • 4.3 Global and historical trends
  • 4.4 7MM forecast methodology

    • 4.4.1 Sources
    • 4.4.2 Forecast assumptions and methods
    • 4.4.3 Forecast assumptions and methods: total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
    • 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD

  • 4.5 Epidemiological Forecast for AMD (2021–31)

    • 4.5.1 Total prevalent cases of AMD
    • 4.5.2 Age-specific total prevalent cases of AMD
    • 4.5.3 Sex-specific total prevalent cases of AMD
    • 4.5.4 Total prevalent cases of early AMD
    • 4.5.5 Total prevalent cases of late AMD
    • 4.5.6 Total prevalent cases of late dry AMD
    • 4.5.7 Total prevalent cases of wet AMD
    • 4.5.8 Diagnosed prevalent cases of AMD
    • 4.5.9 Age-specific diagnosed prevalent cases of AMD
    • 4.5.10 Sex-specific diagnosed prevalent cases of AMD
    • 4.5.11 Diagnosed prevalent cases of early AMD
    • 4.5.12 Diagnosed prevalent cases of late AMD
    • 4.5.13 Diagnosed prevalent cases of late dry AMD
    • 4.5.14 Diagnosed prevalent cases of wet AMD

  • 4.6 Discussion

    • 4.6.1 Epidemiological Forecast Insight
    • 4.6.2 COVID-19 impact
    • 4.6.3 Limitations of the analysis
    • 4.6.4 Strengths of the analysis

• 5 Disease Management

  • 5.1 Diagnosis and Treatment Overview
  • 5.2 KOL Insights on Disease Management

• 6 Competitive Assessment

  • 6.1 Overview

• 7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Longer-acting anti-VEGF therapies
  • 7.3 Treatment for GA
  • 7.4 Availability or accessibility of specialists and patient wait times
  • 7.5 Less invasive drug formulations
  • 7.6 Early diagnosis of patients and increasing awareness of AMD

• 8 R&D Strategies

  • 8.1 Overview

    • 8.1.1 Focus on the development of longer-acting therapies
    • 8.1.2 Diversifying into gene therapies for AMD
    • 8.1.3 Development of cell therapies for AMD

  • 8.2 Clinical Trials Design

    • 8.2.1 Consideration of endpoints for the whole spectrum of AMD

• 9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising drugs in clinical development

• 10 Pipeline Valuation Analysis

  • 10.1 Overview
  • 10.2 Competitive assessment

• 11 Current and Future Players

  • 11.1 Overview
  • 11.2 Deal-making trends

• 12 Market Outlook

  • 12.1 Global markets

    • 12.1.1 Forecast
    • 12.1.2 Drivers and barriers – global issues

  • 12.2 US

    • 12.2.1 Forecast
    • 12.2.2 Key events
    • 12.2.3 Drivers and Barriers

  • 12.3 5EU

    • 12.3.1 Forecast
    • 12.3.2 Key events
    • 12.3.3 Drivers and Barriers

  • 12.4 Japan

    • 12.4.1 Forecast
    • 12.4.2 Key events
    • 12.4.3 Drivers and Barriers

• 13 Appendix

  • 13.1 Bibliography
  • 13.2 Abbreviations
  • 13.3 Methodology

    • 13.3.1 Forecasting methodology

  • 13.4 Primary research – KOLs interviewed for this report

    • 13.4.1 KOLs

  • 13.5 Primary research – prescriber survey
  • 13.6 About the authors

    • 13.6.1 Analyst
    • 13.6.2 Therapy Area Director
    • 13.6.3 Epidemiologist
    • 13.6.4 Managing Epidemiologist/Reviewers
    • 13.6.5 Global Director of Therapy Analysis and Epidemiology

• Contact Us

Table 1: AMD: key metrics in the 7MM

Table 2: Biological pathways associated with AMD risk genes

Table 3: The four-stage AREDS classification of AMD

Table 4: Symptoms of AMD

Table 5: Risk Factors and Comorbid Conditions Associated with AMD

Table 6: Treatment guidelines for AMD

Table 7: Top 10 deals by value, 2016–21

Table 8: AMD market – global drivers and barriers, 2021–31

Table 9: Key events impacting sales for AMD in the US, 2021–31

Table 10: AMD market – drivers and barriers in the US, 2021–31

Table 11: Key events impacting sales for AMD in the 5EU, 2021–31

Table 12: AMD market – drivers and barriers in the 5EU, 2021–31

Table 13: Key events impacting sales for AMD in Japan, 2021–31

Table 14: AMD market – drivers and barriers in Japan, 2021–31

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for AMD in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in AMD during the forecast period

Figure 3: Competitive assessment of recently approved and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period

Figure 4: Comparison of the eye under normal vision and severe vision loss due to AMD

Figure 5: 7MM, Total Prevalence of AMD, Men and Women, Ages ≥50 Years, %, 2021

Figure 6: 7MM, Diagnosed Prevalence of AMD, Men and Women, Ages ≥50 Years, 2021

Figure 7: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD

Figure 9: 7MM, total prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021

Figure 10: 7MM, total prevalent cases of AMD by age, both sexes, N, 2021

Figure 11: 7MM, total prevalent cases of AMD, by sex, ages ≥50 years, N, 2021

Figure 12: 7MM, total prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021

Figure 13: 7MM, total prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021

Figure 14: 7MM, total prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021

Figure 15: 7MM, total prevalent cases of wet AMD, both sexes, ages ≥50 years, N, 2021

Figure 16: 7MM, diagnosed prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021

Figure 17: 7MM, diagnosed prevalent cases of AMD by age, both sexes, N, 2021

Figure 18: 7MM, diagnosed prevalent cases of AMD, by sex, ages ≥50 years, N, 2021

Figure 19: 7MM, Diagnosed prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021

Figure 20: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021

Figure 21: 7MM, diagnosed prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021

Figure 22: 7MM, diagnosed prevalent cases of wet AMD, both sexes, ages ≥50 years, N, 2021

Figure 23: Amsler grid, as viewed by patients with normal vision and with wAMD

Figure 24: Unmet needs and opportunities in AMD

Figure 25: Overview of the development pipeline in AMD

Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for AMD in the 7MM during the forecast period

Figure 27: Competitive assessment of recently approved agents and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period

Figure 28: Competitive assessment of the pipeline drugs benchmarked against the standard of care, Eylea

Figure 29: Analysis of the company portfolio gap in AMD during the forecast period

Figure 30: Global (7MM) sales forecast by country for AMD in 2021 and 2031

Figure 31: Sales forecast by disease subtype for AMD in the US in 2031

Figure 32: Sales forecast for GA in the US in 2031

Figure 33: Sales forecast by class for wAMD in the US in 2021 and 2031

Figure 34: Sales forecast by disease subtype in the 5EU in 2031

Figure 35: Sales forecast by class for wAMD in the 5EU in 2021 and 2031

Figure 36: Sales forecast by class for wAMD in Japan in 2021 and 2031